Larbre, V.; Ranchon, F.; Maucort-Boulch, D.; Coz, E.; Herledan, C.; Caffin, A.-G.; Baudouin, A.; Maire, M.; Romain-Scelle, N.; Vacheron, C.-H.;
et al. Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity. Pharmaceuticals 2025, 18, 565.
https://doi.org/10.3390/ph18040565
AMA Style
Larbre V, Ranchon F, Maucort-Boulch D, Coz E, Herledan C, Caffin A-G, Baudouin A, Maire M, Romain-Scelle N, Vacheron C-H,
et al. Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity. Pharmaceuticals. 2025; 18(4):565.
https://doi.org/10.3390/ph18040565
Chicago/Turabian Style
Larbre, Virginie, Florence Ranchon, Delphine Maucort-Boulch, Elsa Coz, Chloé Herledan, Anne-Gaëlle Caffin, Amandine Baudouin, Magali Maire, Nicolas Romain-Scelle, Charles-Hervé Vacheron,
and et al. 2025. "Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity" Pharmaceuticals 18, no. 4: 565.
https://doi.org/10.3390/ph18040565
APA Style
Larbre, V., Ranchon, F., Maucort-Boulch, D., Coz, E., Herledan, C., Caffin, A.-G., Baudouin, A., Maire, M., Romain-Scelle, N., Vacheron, C.-H., Karlin, L., Salles, G., Ghesquières, H., & Rioufol, C.
(2025). Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity. Pharmaceuticals, 18(4), 565.
https://doi.org/10.3390/ph18040565
